asco 2021 highlights on anti lag3 in advanced melanoma the relativity 047 study
Published 3 years ago • 729 plays • Length 3:12Download video MP4
Download video MP3
Similar videos
-
3:16
#esmo22 highlights on tils versus ipilimumab in patients with advanced melanoma: the phase 3 study
-
6:17
relativity-047: relatlimab, an anti-lag-3 antibody nivolumab in first-line advanced melanoma
-
1:11
highlights for skin cancer at esmo 2021
-
2:17
melanoma highlights from esmo 2021
-
1:43
future directions in melanoma
-
5:01
melanoma highlights from esmo 2021
-
7:02
nivo lag-3 antibody succeeds in advanced melanoma
-
0:57
skin cancer highlights at asco 2022
-
59:56
melanoma highlights from asco
-
3:22
clinical activity of fianlimab, an anti-lag-3 mab combined with cemiplimab in advanced melanoma
-
2:34
highlights in melanoma from asco 2024
-
59:45
melanoma highlights from asco 2020
-
2:59
lag-3 antibody combination in immunotherapy-treated melanoma
-
53:34
asco 2021 clinical panel series - melanoma
-
6:51
success for ipilimumab and nivolumab combo in advanced melanoma
-
1:04
the safety of nivolumab for advanced melanoma
-
42:29
advanced melanoma
-
2:34
what's to come in melanoma at asco 2021?
-
1:25
asco 2014 melanoma